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Background: Alterations at the molecular level in spermatozoa and seminal plasma can affect male fertility. The
objective of this study was to determine if analysis of differential expression of proteins in varying semen
parameters can serve as potential biomarkers for male infertility.
Methods: The differential expression of proteins in the seminal plasma of men based on sperm count and
morphology were examined utilizing proteomic tools. Subjects were categorized based on sperm concentration
and morphology into 4 groups: 1) normal sperm count and normal morphology (NN); 2) normal sperm count and
abnormal morphology (NA); 3) oligozoospermia and normal morphology (ON); and 4) oligozoospermia and
abnormal morphology (OA). Proteomic analysis was performed by LC-MS/MS followed by functional bioinformatics
analysis. Protein distribution in the NA, ON and OA groups was compared with that of the NN group.
Results: Twenty proteins were differentially expressed among the 4 groups. Among the unique proteins identified,
3 were downregulated in the NA group, 1 in the ON group and 1 in the OA group while 2 were upregulated in
the ON and OA groups. The functional analysis 1) identified biological regulation as the major processes affected
and 2) determined that most of the identified proteins were of extracellular origin.
Conclusions: We have identified proteins that are over-or underexpressed in the seminal plasma of men with poor
sperm quality. The distinct presence of some of the proteins may serve as potential biomarkers and provide insight
into the mechanistic role played by these proteins in male infertility. Further studies using Western Blot analysis are
required to validate these findings.Background
Infertility is a major problem in 15% of couples world-
wide. Male factors may play a role in half of these cases
[1]. Most causes of male infertility are idiopathic. Semen
analysis remains the cornerstone in the evaluation of male
infertility. However, the data generated from this routine
testing do not provide any insight into the underlying
problems associated with developing spermatozoa. Sperm
morphology plays an important role in conception, and
both fertilization and pregnancy rates are affected when
morphologically normal sperms are below 5%. It is also a
reflection of poor testicular physiology and is an important
factor in male infertility [2-4]. However, a significant over-
lap of semen parameters such as sperm count, motility and* Correspondence: Agarwaa@ccf.org
1Center for Reproductive Medicine, Glickman Urological and Kidney Institute,
Cleveland Clinic, Cleveland, OH, USA
Full list of author information is available at the end of the article
© 2013 Sharma et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormorphology have been documented [5]. Idiopathic and un-
explained infertility cannot be diagnosed by routine sperm
function tests [6]. Similarly, oligozoospermic men may have
other underlying pathologies that may contribute to infer-
tility. Evaluation solely based on semen analysis is insuffi-
cient to determine the fertility status of the male partner.
Spermatogenesis is a complex process that involves de-
velopment of the undifferentiated germ cells into a highly
specialized spermatozoon capable of fertilizing an oocyte
[7]. Fertilization requires physical proximity of the sperm-
atozoa and the oocytes. Seminal plasma composed of
secretions from the testis, epididymis and male accessory
glands [8] provides a favorable environment and serves as
a vehicle for the spermatozoa as it travels to meet the
oocyte.
Seminal plasma contains unique proteins necessary for
sperm function and survival [9,10]. Seminal plasma pro-
teins play a variety of roles—they help protect the sperml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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play a key role in capacitation, acrosome reaction, and
sperm-egg fusion [11,12]. They can also modulate im-
mune response in male and female reproductive tracts,
ensuring that the most competent spermatozoa meet the
oocyte during fertilization [13]. Thus, seminal plasma
proteins can serve as important biomarkers for male
infertility [14].
Conventional 1-Dimensional gel electrophoresis studies
have provided information in relation to sperm proteins
and their function in normal and abnormal spermato-
zoa [15,16]. Advancements in mass- spectrometry and
proteomic-based techniques have made it possible to
analyze the complex protein mixtures found in tissues
and body fluids. Several attempts have been made to
identify these proteins using high-throughput techniques
such as matrix assisted laser desorption ionization –
time of flight (MALDI-TOF) mass spectrometry (MS)
and liquid chromatography – tandem mass spectrometry
(LC-MS/MS) and linear ion trap (LTQ-Orbitrap) mass
spectrometry [17-21].
Alterations at the molecular level in spermatozoa and
the seminal plasma may contribute to male infertility.
However, even after accounting for all the advances in
proteomics, there has been a great lack of detailed data
in the area of comparative analysis of seminal plasma
proteins associated with male infertility.
The objective of the present study was 1) to compare
the differential expression of proteins in the seminal
plasma from subjects with normal or abnormal sperm
concentration and sperm morphology utilizing proteomic
tools such as LC-MS/MS and 2) utilize the functional bio-
informatics analysis to identify the cellular origin and the
differentially affected processes and/or pathways of these
proteins to gain insights into the mechanistic roles played
by these proteins in effecting the observed phenotypes.
These analyses could possibly identify potential bio-
markers for male infertility.Methods
After obtaining Institutional Review Board approval,
written consent was obtained from all subjects. Semen
samples were obtained from 64 subjects who were
healthy male volunteers of unproven fertility (n = 21)
and men presenting to our infertility clinic for evaluation
(n = 43). Semen samples were collected by masturbation
after 2–3 days of sexual abstinence. Samples with
leukocytospermia--a high concentration of white blood
cells (>1 × 106 WBC/mL)–were examined for the pres-
ence of granulocytes by the peroxidase or the Endtz test.
The patients with a positive Endtz test were excluded
from the study. Semen analysis was conducted according
to WHO criteria as described below [22].Semen analysis
Following complete liquefaction (average time: 20 minutes
and no more than 60 min.), manual semen analysis was
performed using a MicroCell counting chamber (Vitrolife,
San Diego, CA) to determine sperm concentration and
percentage motility according to WHO guidelines [22].
Viability was determined with Eosin - Nigrosin stain.
Smears of the raw semen were stained with a Diff-Quik
kit (Baxter Healthcare Corporation, Inc., McGaw Park, IL)
for assessment of sperm morphology according to WHO
criteria [22].
After analysis of semen parameters, aliquots of the
samples were frozen at −80°C for proteomic analysis.Preparation of samples for proteomic analysis
Samples were divided into 4 groups based only on
normal sperm concentration and normal morphology
parameters according to WHO criteria [22]. The groups
were as follows: Group 1: normal sperm count and
normal morphology (NN = 26); Group 2: normal sperm
count and abnormal morphology (NA = 22); Group 3:
oligozoospermia and normal morphology (ON = 6) and
group 4: oligozoospermia and abnormal morphology
(OA = 10).
To prepare the samples for proteomic analysis, they
were thawed, and clear seminal plasma was separated
from the sperm pellet by centrifugation at 3,000 g for
30 minutes to ensure complete removal of the cellular
components. Seminal plasma samples were pooled into
replicates (NN = 5; NA = 4; ON = 1; OA = 2). Each sam-
ple was dissolved in 98% acetonitrile containing 0.1%
trifluoroacetic acid followed by lyophilization at −80°C
under vacuum for 2 days. The lyophilized sample was
used to estimate the protein content. The samples were
first precipitated in cold acetone and centrifuged at
10,000 g for 15 minutes. The acetone was poured off,
and the protein pellet was allowed to dry at room
temperature. The protein pellet was solubilized in a buf-
fer of 6 M urea, 100 mM Tris, pH 8.0. The proteins were
then reduced by the addition of DTT (200 mM in
100 mM Tris) for 15 minutes at room temperature and
then alkylated by the addition of 200 mM iodoacetamide
(200 mM in 100 mM Tris) for 20 minutes at room
temperature. The urea concentration was then reduced
to approximately 1.2 M, and trypsin was added at a
ratio of 1:50. Digestion was carried out overnight at
room temperature. The digestion was stopped the next
morning by adding acetic acid to lower the pH to <6,
and the samples were centrifuged to remove insoluble
material. The digests were then prepared for LC-MS/MS
analysis by using PepClean C-18 spin columns to desalt
the samples, which were then brought up in 50 μL of 1%
acetic acid.
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(LC-MS/MS)
The LC-MS system is a Finnigan LTQ linear ion trap
mass spectrometer system. The high performance liquid
chromatography (HPLC) column was a self-packed
9 cm × 75 μm (internal diameter) Phenomenex Jupiter
C18 reversed-phase capillary chromatography column.
Ten μL volumes of the extract were injected, and the pep-
tides that were eluted from the column by an acetonitrile/
0.1% formic acid gradient at a flow rate of 0.25 μL/min
were introduced into the source of the mass spectrometer
on-line. The microelectrospray ion source was set at
2.5 kV. The digest was analyzed using the data-dependent
multitask capability of the instrument acquiring full scan
mass spectra to determine peptide molecular weights and
product ion spectra to determine the amino acid sequence
in successive instrument scans [23]. This mode of analysis
produces approximately 2500 collision-induced dissoci-
ation (CID) spectra of ions ranging in abundance over sev-
eral orders of magnitude. The spectral count (SC) for each
protein was determined. Normalized spectral count (NSC)
was obtained by dividing the spectral count for each pro-
tein and the total number of spectral counts identified in
the sample. The spectral counts were quantitated by tak-
ing the normalized spectral count ratio for two sets of
samples. A protein was considered to be differentially
expressed if there was at least a two-fold difference in the
spectral count ratios between the two samples.
Data analysis
All CID spectra collected in the experiment were used to
search the National Center for Biotechnology Information
(NCBI) human reference sequence database with the
search engine MASCOT (Matrix Science, Boston, MA,
www.matrixscience.com). After identification, a database
consisting of all proteins identified in these searches was
created and used for a second set of searches. These
searches were performed with a program called
SEQUEST, and the results from these SEQUEST searches
were used to determine the spectral counts. Furthermore,
functional bioinformatics analysis was done using publicly
available software packages such as Gene Ontology anno-
tations from GO Term Finder [24] and GO Term Mapper
[25], UniProt [26], STRAP [27], and BioGPS [28]) as well
as proprietary software packages (Ingenuity Pathway Ana-
lysis (IPA) from Ingenuity® Systems [29], and Metacore™
from GeneGo Inc. [30]) to identify the differentially
affected processes, pathways, interactions, and cellular
distribution of the proteins in the four study groups.
Results
Analysis of the proteins identified by LC-MS/MS
The proteins identified in the 12 replicates from NN,
NA, ON and OA group showing protein name, NCBIdatabase index, molecular weight, peptide coverage and
Mascot score is shown in Table 1. A protein was consid-
ered significant if the SC cut off value was ≥ 10 in at
least one sample and present in at least 50% of the
samples in a group. They were considered ‘low abun-
dant’ if the SC cut-off value was ≤10 in all the samples.
The differentially expressed proteins (DEP) in the NA,
OA, and ON groups were categorized based on the NSC
ratio cut-off values of > 2 (for over-expressed) or < 0.5
(for under-expressed) in comparison to the NN group.
We identified a total of 35 proteins; of these, 10 were
classified as low abundant. Amongst the remaining 25
significantly abundant proteins (24 in NN, 23 in NA, 20
in OA, and 16 in ON), 11 were present in all the samples,
and 13 proteins were identified as unique to one or two or
three of the four samples. 20 proteins were identified as
differentially expressed in the NA, OA, and ON groups as
compared to NN group, with 2 proteins differentially
expressed in all three groups (Figure 1). The remaining
18 were present in either of the groups (Figure 2). A
detailed list of the proteins classified under these cat-
egories (Common, Unique, Significant, Low Abundant,
and Differentially Expressed) is shown in Table 2.
Identification of the common proteins
Our analyses revealed a set of 11 proteins that were
common to all the samples in the 4 groups (Table 2).
Prolactin induced protein (PIP), semenogelin II (SgII)
precursor, albumin preprotein, lactotransferrin, epididy-
mal secretory protein E1 precursor, extracellular matrix
protein 1 isoform 1 precursor, prosaposin isoform A
preprotein, cathepsin D preprotein, prostate specific
antigen isoform 1 preprotein, zinc alpha-2 glycoprotein
1, and clusterin isoform 1 were the common proteins
identified.
Identification of differentially expressed proteins
As shown in Figure 1, the DEP list encompassed pro-
teins that overlapped with other categories (common,
unique, low abundant and significant). The common
proteins that were also differentially expressed included
prostate specific antigen isoform I preprotein; zinc
alpha-2-glycoprotein 1 and clusterin isoform 1. Five low
abundant proteins (transferrin; secretory leukocyte
peptidase inhibitor precursor; ubiquitin and ribosomal
protein S27a precursor; protein tyrosine phosphatase
receptor type, sigma isoform 1 precursor, and acidic
epididymal glycoprotein-like 1 isoform 1 precursor)
were included as differentially expressed because their
NSC ratio comparison met the 2-fold cutoff criteria.
Of the 20 differentially expressed proteins, mucin 6,
gastric; orosomucoid 1 precursor and acidic epididy-
mal glycoprotein-like isoform 1 precursor were unique
proteins that were down regulated in the NA group.
Table 1 Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI
database index, molecular weight, peptide coverage and Mascot score
Identification LTQ









semenogelin II precursor 4506885 65 9 8(10%) 9536
prolactin induced protein 4505821 16 8.2 3(20%) 5335
albumin preproprotein 4502027 71 5.9 9(22%) 4805
epididymal secretory protein E1 precursor 5453678 16 7.5 3 (21%) 794
prosaposin isoform a preproprotein 11386147 59 5 1 (2%) 658
mucin 6, gastric 151301154 263 7.2 4 (3%) 461
prostate specific antigen isoform 4 preproprotein 71834855 24 7 3 (15%) 460
armadillo repeat protein 4502247 105 6.3 3(5%) 413
cathepsin D preproprotein 4503143 45 6.1 1 (4%) 285
zinc alpha-2-glycoprotein 1 4502337 34 5.7 2 (12%) 260
cystatin S precursor 4503109 16 4.9 2 (31%) 178
ubiquitin and ribosomal protein S27a precursor 4506713 18 9.6 1 (10%) 173
clusterin isoform 1 42716297 58 6.2 3 (10%) 142
Sample NN2
prolactin-induced protein 4505821 16 8.2 10 (69%) 32886
semenogelin II precursor 4506885 65 9 17 (33%) 22468
semenogelin I isoform b preproprotein 38049014 45 9.2 13 (33%) 5388
albumin preproprotein 4502027 71 5.9 24 (54%) 15508
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 11 (61%) 5087
lactotransferrin precursor 54607120 80 8.5 22 (42%) 4281
zinc alpha-2-glycoprotein 1 4502337 34 5.7 11 (44%) 3424
cystatin S precursor 4503109 16 4.9 5 (44%) 1809
prosaposin isoform a preproprotein 11386147 59 5 9 (33%) 880
epididymal secretory protein E1 precursor 5453678 16 7.5 4 (52%) 786
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 11 (48%) 737
mucin 6, gastric 151301154 263 7.2 11 (9%) 524
extracellular matrix protein 1 isoform 1 precursor 221316614 62 6.2 7 (31%) 504
cystatin C precursor 4503107 16 9 6 (68%) 432
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 4 (40%) 411
fibronectin 1 isoform 3 preproprotein 16933542 262 5.4 8(11%) 353
cathepsin D preproprotein 4503143 45 6.1 3 (11%) 266
acid phosphatase, prostate short isoform precursor 6382064 44 5.8 2 (12%) 166
carboxypeptidase E preproprotein 4503009 53 5 5 (20%) 153
clusterin isoform 1 42716297 58 6.2 2 (7%) 106
Sample NN3
prolactin-induced protein 4505821 16 8.2 10 (66%) 24697
semenogelin II precursor 4506885 65 9 19 (35%) 13533
semenogelin I isoform b preproprotein 38049014 45 9.2 15 (39%) 2633
albumin preproprotein 4502027 71 5.9 30 (60%) 8842
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 16 (70%) 8634
lactotransferrin precursor 54607120 80 8.5 23 (49%) 4607
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Table 1 Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI
database index, molecular weight, peptide coverage and Mascot score (Continued)
zinc alpha-2-glycoprotein 1 4502337 34 5.7 9 (42%) 3935
epididymal secretory protein E1 precursor 5453678 16 7.5 6 (52%) 1214
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 3 (29%) 987
prosaposin isoform a preproprotein 11386147 59 5 5 (21%) 833
extracellular matrix protein 1 isoform 1 precursor 221316614 62 6.2 6 (22%) 766
cystatin S precursor 4503109 16 4.9 5 (49%) 621
beta 2 microglobulin precursor 4757826 13 6 2 (21%) 523
fibronectin 1 isoform 3 preproprotein 16933542 262 5.4 4 (2%) 410
orosomucoid 1 precursor 167857790 23 5 3 (16%) 397
cystatin C precursor 4503107 16 9 3 (26%) 301
mucin 6, gastric 151301154 263 7.2 7 (7%) 288
cathepsin D preproprotein 4503143 45 6.1 2 (11%) 228
carboxypeptidase E preproprotein 4503009 53 5 3 (16%) 193
acidic epididymal glycoprotein-like 1 isoform 1 precursor 25121982 29 5.5 2 (10%) 166
galectin 3 binding protein 5031863 66 5.1 4 (11%) 165
clusterin isoform 1 42716297 58 6.2 2 (7%) 158
acid phosphatase, prostate short isoform precursor 6382064 44 5.8 5 (16%) 128
prostaglandin (H2) D-isomerase −1 peptide 32171249 21 7.6 1 (8%) 115
Sample NN4
prolactin-induced protein 4505821 16 8.2 12 (76%) 36052
semenogelin II precursor 4506885 65 9 16 (32%) 17746
semenogelin I isoform b preproprotein 38049014 45 9.2 14 (34%) 2723
lactotransferrin precursor 54607120 80 8.5 39 (61%) 8695
albumin preproprotein 4502027 71 5.9 23 (48%) 8361
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 15 (67%) 7417
zinc alpha-2-glycoprotein 1 4502337 34 5.7 11 (38%) 3979
mucin 6, gastric 151301154 263 7.2 14 (12%) 1685
epididymal secretory protein E1 precursor 5453678 16 7.5 7 (70%) 1428
acid phosphatase, prostate short isoform precursor 6382064 44 5.8 9 (26%) 1384
clusterin isoform 1 42716297 58 6.2 6 (16%) 1148
orosomucoid 1 precursor 167857790 23 5 4 (32%) 942
orosomucoid 2 4505529 23 5 2 (12%) 207
prosaposin isoform a preproprotein 11386147 59 5 6 (27%) 941
extracellular matrix protein 1 isoform 1 precursor 221316614 62 6.2 7 (25%) 731
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 3 (29%) 635
beta 2 microglobulin precursor 4757826 13 6 2 (21%) 489
fibronectin 1 isoform 3 preproprotein 16933542 262 5.4 4 (3%) 447
cystatin C precursor 4503107 16 9 3 (26%) 391
carboxypeptidase E preproprotein 4503009 53 5 4 (14%) 358
galectin 3 binding protein 5031863 66 5.1 5 (14%) 341
transferrin 4557871 79 6.8 2 (4%) 275
acidic epididymal glycoprotein-like 1 isoform 1 precursor 25121982 29 5.5 2 (10%) 238
cystatin S precursor 4503109 16 4.9 2 (20%) 205
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 3 (12%) 187
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Table 1 Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI
database index, molecular weight, peptide coverage and Mascot score (Continued)
cathepsin D preproprotein 4503143 45 6.1 2 (11%) 185
prostaglandin (H2) D-isomerase −1 peptide 32171249 21 7.6 1 (8%) 133
Sample NN5
prolactin-induced protein 4505821 16 8.2 8 (44%) 15001
semenogelin II precursor 4506885 65 9 10 (14%) 7235
albumin preproprotein 4502027 71 5.9 17 (39%) 2621
epididymal secretory protein E1 precursor 5453678 16 7.5 3 (23%) 552
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 5 (22%) 539
cystatin S precursor 4503109 16 4.9 2 (23%) 332
zinc alpha-2-glycoprotein 1 4502337 34 5.7 4 (19%) 250
prosaposin isoform a preproprotein 11386147 59 5 1 (2%) 239
prostatic acid phosphatase precursor 6382064 44 5.8 2 (4%) 180
lactotransferrin 54607120 80 8.5 4 (10%) 173
clusterin isoform 1 42716297 58 6.2 2 (7%) 157
galectin 3 binding protein 5031863 66 5.1 2 (4%) 152
extracellular matrix protein 1 isoform 1 precursor 4758236 62 6.2 1 (5%) 119
Sample NA1
prolactin-induced protein 4505821 16 8.2 10 (62%) 17127
albumin preproprotein 4502027 71 5.9 36 (61%) 9157
semenogelin II precursor 4506885 65 9 22 (39%) 7469
semenogelin I isoform b preproprotein 38049014 45 9.2 19 (42%) 2622
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 14 (67%) 5287
lactotransferrin 54607120 80 8.5 19 (40%) 2696
zinc alpha-2-glycoprotein 1 4502337 34 5.7 9 (38%) 1904
epididymal secretory protein E1 precursor 5453678 16 7.5 6 (68%) 1228
extracellular matrix protein 1 isoform 1 precursor 221316614 62 6.2 6 (22%) 635
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 8 (27%) 616
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 2 (19%) 487
prosaposin isoform a preproprotein 11386147 59 5 4 (15%) 475
beta 2 microglobulin precursor 4757826 13 6 2 (21%) 400
fibronectin 1 isoform 3 preproprotein 16933542 262 5.4 7 (5%) 398
cystatin C precursor 4503107 16 9 3 (26%) 340
cystatin S precursor 4503109 16 4.9 2 (20%) 261
mucin 6, gastric isoform 1 89033736 185 6.3 4 (5%) 238
prostaglandin (H2) D-isomerase 32171249 21 7.6 1 (8%) 227
prostatic acid phosphatase precursor 6382064 44 5.8 4 (8%) 189
protein tyrosine phosphatase, receptor type, sigma isoform 1
precursor
104487006 218 6.1 5 (5%) 180
transferrin 4557871 79 6.8 3 (17%) 174
clusterin isoform 1 42716297 58 6.2 4 (11%) 171
cathepsin D preproprotein 4503143 45 6.1 1 (4%) 149
galectin 3 binding protein 5031863 66 5.1 5 (14%) 101
Sample NA2
prolactin-induced protein 4505821 16 8.2 12 (76%) 21197
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Table 1 Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI
database index, molecular weight, peptide coverage and Mascot score (Continued)
semenogelin II precursor 4506885 65 9 18 (36%) 9137
semenogelin I isoform b preproprotein 38049014 45 9.2 13 (33%) 1777
albumin preproprotein 4502027 71 5.9 26 (55%) 7695
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 16 (67%) 4963
zinc alpha-2-glycoprotein 1 4502337 34 5.7 13 (44%) 3134
lactotransferrin 54607120 80 8.5 24 (46%) 3105
epididymal secretory protein E1 precursor 5453678 16 7.5 5 (68%) 1276
prosaposin isoform a preproprotein 11386147 59 5 7 (26%) 662
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 3 (29%) 660
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 5 (20%) 612
extracellular matrix protein 1 isoform 1 precursor 4758236 62 6.2 7 (22%) 577
cystatin C precursor 4503107 16 9 3 (26%) 548
beta 2 microglobulin precursor 4757826 13 6 2 (21%) 443
prostatic acid phosphatase precursor 6382064 44 5.8 8 (18%) 410
cathepsin D preproprotein 4503143 45 6.1 5 (25%) 375
clusterin isoform 1 42716297 58 6.2 2 (7%) 308
DJ-1 protein 31543380 20 6.3 2 (26%) 279
carboxypeptidase E preproprotein 4503009 53 5 4 (19%) 278
galectin 3 binding protein 5031863 66 5.1 5 (14%) 266
cystatin S precursor 4503109 16 4.9 6 (64%) 212
CD177 molecule 110735433 47 5.6 2 (9%) 199
mucin 6, gastric isoform 1 89033736 185 6.3 3 (4%) 196
fibronectin 1 isoform 3 preproprotein 16933542 262 5.4 4 (4%) 172
secretory leukocyte peptidase inhibitor precursor 4507065 15 9.1 2 (28%) 162
cathepsin B preproprotein 4503139 38 5.8 3 (12%) 127
Sample NA3
prolactin-induced protein 4505821 16 8.2 5 (37%) 6642
semenogelin II precursor 4506885 65 9 6 (9%) 5126
albumin preproprotein 4502027 71 5.9 7 (17%) 2077
prosaposin isoform a preproprotein 11386147 59 5 2 (8%) 438
mucin 6, gastric isoform 1 89033736 185 6.3 3 (2%) 269
epididymal secretory protein E1 precursor 5453678 16 7.5 2 (21%) 210
zinc alpha-2-glycoprotein 1 4502337 34 5.7 3 (24%) 203
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 3 (13%) 141
clusterin isoform 1 42716297 58 6.2 3 (10%) 117
Sample NA4
prolactin-induced protein 4505821 16 8.2 10(76%) 22296
semenogelin II precursor 4506885 65 9 16 (30%) 11486
semenogelin I isoform b preproprotein 38049014 45 9.2 13 (33%) 3038
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 14 (67%) 3631
zinc alpha-2-glycoprotein 1 4502337 34 5.7 11 (38%) 3260
lactotransferrin 54607120 80 8.5 16 (45%) 2926
prosaposin isoform a preproprotein 11386147 59 5 5 (20%) 773
epididymal secretory protein E1 precursor 5453678 16 7.5 3 (39%) 533
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Table 1 Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI
database index, molecular weight, peptide coverage and Mascot score (Continued)
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 4 (12%) 506
extracellular matrix protein 1 isoform 1 precursor 4758236 62 6.2 4 (17%) 454
beta 2 microglobulin precursor 4757826 13 6 2 (21%) 388
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 3 (29%) 351
cystatin S precursor 4503109 16 4.9 5 (48%) 321
cystatin C precursor 4503107 16 9 2 (26%) 280
cathepsin D preproprotein 4503143 45 6.1 2 (11%) 200
cathepsin B preproprotein 4503139 38 5.8 2 (10%) 186
carboxypeptidase E preproprotein 4503009 53 5 3 (11%) 162
Sample OA1
prolactin-induced protein 4505821 16 8.2 12 (77%) 22670
semenogelin II precursor 4506885 65 9 19(32%) 13764
semenogelin I isoform b preproprotein 38049014 45 9.2 15 (27%) 6586
albumin preproprotein 4502027 71 5.9 26 (51%) 7715
lactotransferrin 54607120 80 8.5 28 (54%) 5063
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 11 (64%) 3309
zinc alpha-2-glycoprotein 1 4502337 34 5.7 9 (40%) 3298
ankyrin repeat domain 11 56676397 299 6.7 3 (1%) 1056
PREDICTED: mucin 6, gastric isoform 1 89033736 185 6.3 10 (14%) 808
epididymal secretory protein E1 precursor 5453678 16 7.5 7 (70%) 635
clusterin isoform 1 42716297 58 6.2 4 (13%) 512
fibronectin 1 isoform 2 preproprotein 47132551 269 5.3 10 (7%) 503
extracellular matrix protein 1 isoform 1 precursor 4758236 62 6.2 5 (28%) 420
prosaposin isoform a preproprotein 11386147 59 5 4 (18%) 407
prostatic acid phosphatase precursor 6382064 44 5.8 9 (28%) 365
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 4 (35%) 337
beta 2 microglobulin precursor – 1 peptide 4757826 13 6 1 (18%) 262
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 4 (12%) 242
transferrin 4557871 79 6.8 3 (4%) 211
cathepsin D preproprotein 4503143 45 6.1 2 (11%) 206
cystatin C precursor 4503107 16 9 5 (52%) 199
cystatin S precursor 4503109 16 4.9 6 (68%) 198
secretory leukocyte peptidase inhibitor precursor −1 peptide 4507065 15 9.1 1 (18%) 175
carboxypeptidase E preproprotein 4503009 53 5 2 (8%) 123
galectin 3 binding protein 5031863 66 5.1 3 (8%) 105
cathepsin B preproprotein 4503139 38 5.8 2 (12%) 95
expressed in prostate and testis 19923082 14 8.2 1 (10%) 86
macrophage migration inhibitory factor – 1 peptide 4505185 12 7.7 1 (9%) 84
prostaglandin (H2) D-isomerase −1 peptide 32171249 21 7.6 1 (8%) 75
Sample OA2
prolactin-induced protein 4505821 16 8.2 8 (51%) 13511
semenogelin II precursor 4506885 65 9 11 (18%) 6235
albumin preproprotein 4502027 71 5.9 10 (23%) 1848
cystatin S precursor 4503109 16 4.9 3 (28%) 522
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Table 1 Identification of proteins in the 12 replicates from NN, NA, ON and OA group showing protein name, NCBI
database index, molecular weight, peptide coverage and Mascot score (Continued)
prostate specific antigen isoform 4 preproprotein 71834855 24 7 4 (25%) 354
prosaposin isoform a preproprotein 11386147 59 5 1 (2%) 324
clusterin isoform 1 42716297 58 6.2 3 (10%) 308
mucin 6, gastric isoform 1 89033736 185 6.3 2 (1%) 306
zinc alpha-2-glycoprotein 1 4502337 34 5.7 4 (17%) 291
epididymal secretory protein E1 precursor 5453678 16 7.5 3 (38%) 184
ankyrin repeat domain 11 56676397 299 6.7 3 (1%) 133
carboxypeptidase E preproprotein 4503009 53 5 2 (8%) 121
lactotransferrin precursor 54607120 80 8.5 3 (9%) 115
extracellular matrix protein 1 isoform 1 precursor 4758236 62 6.2 1 (5%) 108
galectin 3 binding protein 5031863 66 5.1 1 (2%) 98
cathepsin D preproprotein 4503143 45 6.1 2 (13%) 95
lactamase, beta isoform a 26051231 61 8.7 2 (10%) 90
prostatic acid phosphatase precursor 6382064 44 5.8 1 (4%) 78
Sample ON
prolactin-induced protein 4505821 16 8.2 9 (69%) 33212
semenogelin II precursor 4506885 65 9 20 (35%) 10703
semenogelin I isoform b preproprotein 38049014 45 9.2 17 ((38%) 2722
albumin preproprotein 4502027 71 5.9 25 (52%) 9519
prostate specific antigen isoform 1 preproprotein 4502173 29 7.6 14 (62%) 6487
zinc alpha-2-glycoprotein 1 4502337 34 5.7 9 (38%) 5967
lactotransferrin precursor 54607120 80 8.5 18(40%) 3770
serine proteinase inhibitor, clade A, member 1 50363217 46 5.3 4 (15%) 1138
prosaposin isoform a preproprotein 11386147 59 5 6 (26%) 1014
epididymal secretory protein E1 precursor 5453678 16 7.5 3 (39%) 937
tissue inhibitor of metalloproteinase 1 precursor 4507509 23 8.4 2 (19%) 866
extracellular matrix protein 1 isoform 1 precursor 221316614 62 6.2 3 (12%) 637
beta 2 microglobulin precursor 4757826 13 6 2 (21%) 633
mucin 6, gastric 151301154 263 7.2 5 (5%) 407
fibronectin 1 isoform 3 preproprotein 16933542 262 5.4 2 (1%) 352
cathepsin D preproprotein 4503143 45 6.1 2 (11%) 334
cystatin C precursor 4503107 16 9 3 (26%) 320
carboxypeptidase E preproprotein 4503009 53 5 3 (11%) 172
clusterin isoform 1 42716297 58 6.2 2 (7%) 147
acid phosphatase, prostate short isoform precursor 6382064 44 5.8 3 (8%) 132
secretory leukocyte peptidase inhibitor precursor 4507065 15 9.1 2 (42%) 123
protein tyrosine phosphatase, receptor type, sigma isoform 1
precursor
104487006 218 6.1 4 (3%) 112
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the OA group were: prostate specific antigen isoform
1 preprotein; semenogelin I isoform b preprotein.
Cystatin C precursor was found to be downregulated
in the OA group. The ON group showed an
upregulation of two unique proteins (zinc alpha-2
glycoprotein 1 and tissue inhibitor of metalloproteinase1 precursor); while clusterin 1 was downregulated in
this group.
Some unique proteins were absent in some of the
groups but were differentially expressed in other groups.
These proteins included the DJ-1 protein, which was
absent in the OA groups, whereas the ankyrin repeat
domain 11 was absent in the NN group. Also included
Figure 1 Broad categorical analysis of proteomics data. Differentially expressed proteins list encompasses proteins that overlap with other
categories (common, unique, low abundant and significant) of proteins.
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was found in significant abundance in the NN samples
but in low abundance in NA sample.
Identification of the low abundant proteins
Many of the identified proteins were low abundant
proteins (SC ≤10) (Table 2). Some of these proteins were
restricted to a particular group while they were absent in
other groups. Transferrin, secretory leukocyte peptidase
inhibitor precursor, ubiquitin and ribosomal protein
S27 a precursor, prostaglandin H2 D isomerase were
some of the proteins that were absent in ON group.
The CD177 molecule was absent only in the NN group;Figure 2 Venn diagram showing distribution of 20 differentially expre
samples, NA, OA, and ON in comparison to the baseline NN sample.while orosomucoid 2 was present only in the NN. Pro-
tein tyrosine phosphatase, receptor type, sigma isoform
1 precursor and acidic epididymal glycoprotein - like 1
isoform 1 precursor protein were absent in the OA
group.
Cellular distribution and significant biological processes
for proteins in four groups
The functional analysis revealed that most of the signifi-
cant proteins in each of the four groups (NN, NA, OA,
and ON) had a predominant cellular distribution in the
extracellular region followed by their presence in the
intracellular organelles (Figure 3). The distribution ofssed proteins. This was based on the NSC ratio cut-off >2 across 3
Table 2 Detailed list of classification of 35 proteins based on their presence, abundance, and differential expression









































5 epididymal secretory protein
E1 precursor





6 extracellular matrix protein 1
isoform 1 precursor





7 prosaposin isoform a
preproprotein










9 prostate specific antigen
isoform 1 preproprotein
4502173 Q546G3 12 NN(5), NA
(4), OA(2),
ON(1)
↑ in OA NN, NA, OA,
ON
10 zinc alpha-2-glycoprotein 1 4502337 P25311 12 NN(5), NA
(4), OA(2),
ON(1)
↑ in ON NN, NA, OA,
ON
11 clusterin isoform 1 42716297 P10909 12 NN(5), NA
(4), OA(2),
ON(1)
Low in ON ↓ in ON NN, NA, OA
12 mucin 6, gastric 151301154 Q6W4X9 11 NN(4), NA
(4), OA(2),
ON(1)
↓ in NA NN, NA, OA,
ON
13 cystatin S precursor 4503109 P01036 11 NN(4), NA
(4), OA(2),
ON(1)
Low in ON ↓ in NA, OA, ON NN, NA, OA





↓ in OA, ON NN, NA
15 semenogelin I isoform b
preproprotein
38049014 P04279 10 NN(3), NA
(4), OA(2),
ON(1)
↑ in OA NN, NA, OA,
ON
16 prostatic acid phosphatase
precursor
6382064 P15309 10 NN(4), NA
(3), OA(2),
ON(1)
Low in ON ↓in NA, ON NN, NA, OA
17 cystatin C precursor 4503107 P01034 9 NN(4), NA
(3), OA(1),
ON(1)
↓in OA NN, NA, OA,
ON
18 tissue inhibitor of
metalloproteinase 1
precursor
4507509 Q6FGX5 8 NN(3), NA
(3), OA(1),
ON(1)
↑ in ON NN, NA, OA,
ON
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Table 2 Detailed list of classification of 35 proteins based on their presence, abundance, and differential expression
(Continued)
19 beta 2 microglobulin
precursor
4757826 P61769 8 NN(3), NA
(3), OA(1),
ON(1)
Low in OA ↓ in OA; Up in ON NN, NA, ON
20 DJ-1 protein 31543380 Q99497 6 NN(2), NA
(3), ON(1)
↑ in NA, ON NN, NA, ON




↓ in OA, ON OA
22 orosomucoid 1 precursor 167857790 P02763 2 NN(2), NA
(1)
Low in NA ↓in NA NN
23 serine proteinase inhibitor,
clade A, member 1
50363217 P01009 8 NN(3), NA
(3), OA(1),
ON(1)
↑ in NA,ON; ↓ in OA NA, OA, ON




↑ in NA, OA NONE
25 secretory leukocyte
peptidase inhibitor precursor




↑ in NA, OA NONE
26 ubiquitin and ribosomal
protein S27a precursor




↓ in NA, OA NONE
27 protein tyrosine
phosphatase, receptor type,
sigma isoform 1 precursor




↑ in NA, ON NONE
28 acidic epididymal
glycoprotein-like 1 isoform 1
precursor





29 prostaglandin H2 D-
isomerase










31 expressed in prostate and
testis





32 orosomucoid 2 4505529 P19652 1 NN(1) Low
abundant
NONE














35 fibronectin 1 isoform 2
preproprotein
47132551 P02751 10 NN(4), NA
(4), OA(1),
ON(1)
Low in ON NN, NA, OA
NN = normal sperm count and normal morphology; NA = normal sperm count and abnormal morphology; ON = oligozoospermia and normal morphology;
OA = oligozoospermia and abnormal morphology; number in the parenthesis indicates the number of samples.
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cases to the NN group but was different from the ON
and OA groups. The OA group showed only ~15% of
the proteins localized in the plasma membrane region
compared to the other groups, with the maximum num-
ber of proteins (~20%) localized in the lysosomal and
vacuolar regions. The ON group showed the least distri-
bution of proteins in the nuclear region compared to the
extracellular region.
The functional analysis of the significant proteins in
each of the groups revealed that most of the proteinsinvolved in the biological process were regulatory in
function (Figure 4). Based on the distribution pattern of
the regulatory proteins, the OA groups showed the least
involvement of proteins (60%) in regulation compared
with 70% - 75% seen in the NN, NA and ON groups. A
smaller number of proteins were involved in other func-
tional processes such as protein complex assembly, cell
morphogenesis, membrane organization, protein matur-
ation and trafficking in all the 4 groups. Interestingly,
none of the proteins in the ON group were involved in
any of these processes. Importantly, of all the major
Figure 3 Functional annotations from consolidated findings using publicly available software tools (GO term mapper, GO term finder,
UniProtKB, STRAP, BioGPS) and proprietary pathway software packages (Ingenuity Pathway Analysis and Metacore™) showing cellular
distribution of significant proteins in NN, NA, OA, and ON groups.
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distribution of signal transduction proteins (15%) and
had little or no role in neurological system processing,
membrane organization and protein maturation.
Comparison of cellular distribution and biological
processes amongst the common, DEP, and low abundant
proteins
A detailed evaluation of the cellular localization of the
common, DEP and low abundant proteins is shown in
Figure 5. A higher distribution of the common proteins
was seen in the majority of cellular compartmentsFigure 4 Functional annotations from consolidated findings using pu
UniProtKB, STRAP, BioGPS) and proprietary pathway software packag
biological processes of significant proteins in NN, NA, OA and ON grocompared to DEP and low abundance proteins. The
extracellular region showed the highest distribution
(91%) of the common proteins whereas they were
absent in the ribosomal and endosomal regions. Higher
distribution of differentially expressed proteins was seen
in the cytosolic and Golgi regions compared to the
common or low abundance proteins. The low abundant
proteins were absent in the protein complex and
secretory granular region but their localization was
found to be high in the nuclear and endosomal regions.
A comparative analysis of the proteins involved in
various biological processes in the three groups areblicly available software tools (GO term mapper, GO term finder,
es (Ingenuity Pathway Analysis and Metacore™) showing
up.
Figure 5 Functional annotations from consolidated findings using publicly available software tools (GO term mapper, GO term finder,
UniProtKB, STRAP, BioGPS) and proprietary pathway software packages (Ingenuity Pathway Analysis and Metacore™) showing
comparison of cellular distribution amongst the proteins in Common, DEP, and Low abundant category.
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all 4 groups played a significant role in many of the bio-
logical processes such as cellular development, molecu-
lar transport, and stress response, interactions with cells
and organisms, cellular processes and in processes relat-
ing to the immune system. Compared with the common
proteins, DEP were comparable for the regulatory pro-
cesses, but were reduced in all biological processes.
Higher distribution was seen in protein metabolic
process, vesicle mediated transport, defense response
and cellular protein modification process. The low abun-
dant proteins were seen to be involved mainly in proteinFigure 6 Functional annotations from consolidated findings using pu
UniProtKB, STRAP, BioGPS) and proprietary pathway software packag
Comparison of Biological Processes amongst the proteins in Commonmetabolism, vesicle-mediated transport and defense
response.
Pathways and network analysis using IPA and metacore™
Based on the dataset derived from common, DEP and
low abundance proteins, pathways, biological functions
and networks of interactions were derived utilizing the
two proprietary pathway packages, IPA and Metacore™.
The important processes affected by common proteins
were lipid metabolism (epididymal secretory protein E1
precursor, prosaposin isoform A preprotein, clusterin
isoform 1, lactotransferrin and cathepsin D preprotein),blicly available software tools (GO term mapper, GO term finder,
es (Ingenuity Pathway Analysis and Metacore™) showing
, DEP, and Low abundant category.
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transferrin, clusterin isoform 1, prosaposin isoform A
preprotein and prostate specific antigen isoform 1
preprotein), and cellular development (clusterin isoform
1, prostate specific antigen isoform 1 preprotein, lacto-
transferrin, extracellular matrix protein 1 isoform 1 pre-
cursor, cathepsin D preprotein and epididymal secretory
protein E1 precursor).
The important processes affected by DEP showed a
higher involvement in carbohydrate metabolism and
nephrosis (ankyrin repeat domain 11, beta 2 microglobulin
(B2MG) precursor, clusterin isoform 1, cystatin C pre-
cursor, prostate specific antigen isoform 1 preprotein,
DJ-1 protein, protein tyrosine phosphatase, receptor
type, sigma isoform 1 precursor, transferrin). The major
pathways involved are proteolysis (extracellular matrix;
ECM), remodeling and connective tissue degradation,
immune response, clathrin-mediated endocytosis sig-
naling, lipid antigen presentation by CD1, and intrinsic
prothrombin activation pathway. Similarly, in the low
abundant proteins the top biological functions included
the cellular development, growth proliferation, DNA
replication, recombination, and repair (prostaglandin (H2)
D-isomerase, protein tyrosine phosphatase, receptor type,
sigma isoform 1 precursor and transferrin).
We also studied the major biological functions of the
DEP in each of the 3 groups and found that free radical
scavenging was the topmost function in the NA group,
while cell-to-cell signaling and interaction were seen in
all 3 groups. Genes that encode for 7 differentially
expressed proteins (cysteine-rich secretory protein 1,
clusterin, prostatic acid phosphatase (PAP), mucin 6, pros-
tate specific antigen (PSA), zinc alpha-2-glycoprotein 1,
and DJ-1) are known to be regulated by androgen recep-
tor. The transcriptional network showed the activation
of prostate induction by the androgen receptor signaling
pathway. DJ-1 protein, protein tyrosine phosphatase,
receptor type, sigma isoform 1 precursor and transferrin
were observed to interact with other proteins in the
pathway database and affect processes related to cellular
function and maintenance. Similarly, in the OA group,
prostate specific antigen isoform 1 preprotein and
transferrin formed the topmost network, encompassing
key processes such as gene expression, tissue morphology
and cell cycle. The ON group showed immunological dis-
ease, antigen presentation, cell-to-cell signaling and inter-
action (B2MG precursor, DJ-1 protein, receptor type,
sigma isoform 1 precursor) as the key processes affected
in its topmost network
Discussion
Seminal plasma is a mixture of secretions of several male
accessory glands, including prostate, seminal vesicles,
epididymis and Cowper’s gland. Prostate gland is a majorcontributor to seminal plasma. It is a very rich source of
protein with concentration ranges from 35 to 55 g/l
[9,10]. It provides a safe environment for spermatozoa to
carry out their physiological functions. Understanding
the protein profile of human seminal plasma is import-
ant because it has a profound impact on sperm physi-
ology and thus may affect sperm functioning [31].
In this novel study, we identified 35 proteins based on
SEQUEST scoring in the seminal plasma of men with
varying semen parameters and categorized them into
common, differentially expressed, and low abundant
proteins. The large variation in the number of proteins
identified by any given technique depends mainly on the
sample preparation and mass spectrometry technology
available [32-36]. Recently, the LTQ-Orbitrap mass
spectrometer has become the cutting-edge instrument
for LC/MDS/MS based approaches to characterize the
seminal proteome. In our study, we used in-solution
digestion of proteins with the online LC-MS system.
Seminal plasma from different subsets was pooled to
form 4 distinct study groups. There are numerous stud-
ies in the proteomic literature that refer to the benefits
of pooling samples where it may not be feasible to
analyze individual samples due to limitations of the sample
or the study design [8,17,37,38].
Of the 11 proteins found in all the samples, 9 were
associated with sperm function, and the common pro-
teins comprised the majority of the secretions of the
prostate gland, the seminal vesicles and epididymis.
Some of the proteins or their isoforms detected in the
seminal plasma were zinc alpha-2-glycoprotein 1, clusterin,
lactotransferrin, prostate specific antigen. These were simi-
lar to those reported by Utleg et al. [39].
Prostate specific antigen is a serine protease that
cleaves semenogelin by hydrolysis and thus liquefies the
semen coagulum and facilitates sperm motility and cap-
acitation [40,41]. Our study showed that prostate specific
antigen isoform I preprotein was one of the common
proteins, thus indicating its importance in all the 4
groups. Prolactin-induced protein (PIP) and Sg II are
important common proteins that have a profound im-
pact on sperm physiology. PIP has specificity to fibro-
nectin and constitutes about 1% of seminal coagulum
[42]. It may play a vital role in fibronectin breakdown
during liquefaction. Viscous samples have been reported
to show reduced amounts of PIP and PIP precursor,
which may also be a contributory factor towards incom-
plete liquefaction [43]. Both Sg I and II are the major
proteins of the coagulum. They represent 20-40% of the
seminal plasma proteins. Studies have shown increased
Sg concentrations in asthenozoospermic men [44,45].
Our study showed that both prolactin and semenogelin
II were in all samples but they were not differentially
expressed, indicating that men with low sperm count or
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teins—a conclusion also made by Milardi et al. [18].
Epididymal secretory protein E I precursor, albumin
preprotein, lactotransferrin, extracellular matrix protein
E1 precursor, prosaposin isoform a preprotein, cathepsin
D preprotein were some of the commonly expressed
proteins that were not differentially expressed in any of
the groups, suggesting that these proteins may not play
a significant role in sperm concentration or morphology.
The highest percentage of the common proteins was
seen in the extracellular region (Figure 5). Human sem-
inal plasma proteins can bind to sperm surface proteins
in the ejaculate and form a protective layer around the
spermatozoon [12] as well as a sperm reservoir in the
oviduct [46]. It is likely that the extracellular origin of
most of the common proteins may play a key role in the
binding activity of the proteins. The absence of common
proteins in the ribosomal and endosomal region (Figure 5)
suggests a relatively low involvement in protein metab-
olism, as also seen by the low distribution of common
proteins in the ‘protein metabolic process’ category,
(Figure 6). Zinc alpha-2 glycoprotein and clusterin play
a role in signal transduction while lactotransferrin is a
transport and structural protein [39]. Prostate specific
antigen has been shown to have enzymatic activity. Our
results show a high distribution of signal transducing
protein among the common proteins, suggesting the
importance of clusterin, isoform 1 and zinc alpha-2
glycoprotein 1 (Figure 6). This was also confirmed from
the pathway and network analysis, which also
highlighted the role these proteins play in molecular
transport, cell death and survival and lipid metabolism.
A clear overlap was observed for some of the differen-
tially expressed proteins. These included the prostate spe-
cific antigen isoform 1 preprotein, zinc alpha 2 glycoprotein
1, and clusterin isoform 1. While semenogelin II precursor
was seen in common proteins, the semenogelin I isoform b
preprotein was found to be upregulated in the OA group.
This suggests that it may contribute to the low motility
seen in this group compared to other groups.
Clusterin isoform was downregulated in the ON
group. This is an interesting finding, given that clusterin
isoform 1 has been shown to be downregulated in pros-
tate cancer. The proteome of the seminal fluid is largely
attributed to secretions from the prostate gland, and
approximately 10% is contributed by the testis and the
epididymis [8].
Prostate gland is a major contributor to seminal plasma.
Furthermore, one of the proteins - prostatic acid phos-
phatase (PAP) was significantly increased in azoospermic
men compared to oligozoospermic men and asthenozoo-
spermic men [10]. In our study, PAP levels were down
regulated in the NA and ON groups. PAP levels have also
been reported to correlate with sperm concentration[47-49]. Patients with severe oligozoospermia (<1 × 106)
were also shown to have increased levels of seminal PAP
[50]. PAP is produced in the prostate gland and is present
in the seminal fluid at a concentration of 1 mg/mL. It is
an important tumor marker and acts as a negative growth
regulator in prostate cancer [51].
A proteomic analysis of seminal fluid, rather than
blood, has been proposed as as a better starting point to
identify changes that may serve as specific and sensitive
markers of prostate dysfunction [17]. These authors iden-
tified more than 100 proteins such as PSA, semenogelin I
and II, clusterin etc. which have been shown to affect
sperm quality.
The increased expression of semenogelin I in the OA
group suggests that the accessory gland secretions have
a profound impact on oligozoospermic men with abnor-
mal morphology. Wang et al. reported semenogelin I
and mucin were not differentially expressed and there-
fore had no effect in asthenozoospermic men [21]. Our
study also included the differentially expressed proteins,
especially DJ-1 secreted from the testis, epididymis and
prostate [39,52]. DJ-1 has a high level of expression in
the testis. We found DJ-1 to be overexpressed in the NA
and ON groups. We also documented that orosomucoid 1
precursor was downregulated in the NA group whereas
expression of orosomucoid 2 was comparable in all
groups, though it was present in low abundance. However,
Wang et al. reported the overexpression of orosomucoid 1
and orosomucoid 2 in asthenozoospermic patients [21].
These proteins have also been found in high abundance in
post vasectomy patients [8].
B2MG was found to be under-expressed in OA while
over-expressed in the ON samples. B2MG is present in
all nucleated cells. It is one of the two polypeptide
chains of the major histocompatiblity complex (MHC)
class I molecule. In humans B2MG is coded by the B2M
gene. It is a marker of cellular immune system. It is a
naturally occurring protein and can detect certain types
of tumor cells in the blood and kidney, and some inflam-
matory and autoimmune disorders [53,54]. In our study
as well as that reported by Fung et al. [17], many of the
proteins in the seminal plasma were identified to be fore-
runners of prostate disease, suggesting a pathogenic role
for B2MG [55,56]. Similarly high levels of B2MG were
reported in the seminal plasma of azoospermic men com-
pared to controls [10,57,58]. An inverse correlation was
reported between B2MG levels in seminal fluid and sperm
count [10].
Similary, we reported the underexpression of galectin
3 binding protein in oligozoospermic group. Galectin-3
is a carbohydrate-binding protein whose expression level
has been shown to correlate with metastatic potential in
a number of different types of tumors. Galectin-3 is
downregulated in prostate cancer. The altered
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tumor stages suggests different roles for galectin-3 in the
progression of prostate cancer [59].
TIMP 1 can inhibit tumor growth, invasion and me-
tastasis through their matrix metalloproteinases (MMP)
inhibitory activity [60,61]. TIMPs play an inhibitory role,
and any imbalance between the two may result in pro-
gression of the disease [62]. TIMP was found to be over-
expressed in the ON group.
Amongst the proteins that were uniquely under-
expressed in the OA group was ankyrin repeat domain
11 (ANKRD11). Ankyrins function as adaptor proteins
[63,64] and play a vital role in membrane skeleton
organization, ionic transport, maintenance of cell polar-
ity as well as cell-cell adhesion regulation. Data suggest
that ANKRD11 may act as a tumor suppressor [65]. It’s
presence in the semen samples has not been well docu-
mented, but it is likely that its overexpression in
oligozoospermic men may play a role in apoptosis.
Clusterin isoform 1 can be both pro- and antiapoptotic
depending upon the isoform expressed [66,67]. It plays a
key role in signal transduction and is involved in apop-
tosis of spermatocytes, sperm maturation, and
spermiation. Low signal transducing proteins were seen
in the OA group compared with the other groups, as
shown in Figure 4.
Compared with the proteins involved in stress response,
as elucidated from GO annotations (Figure 4), the NA and
ON groups had a higher distribution of stress proteins
such as DJ-1 whereas a lower distribution of this protein
was seen in OA group. DJ-1 protein is a multifunctional,
highly conserved antioxidant protein and is upregulated in
hyperglycemia [68,69]. It is mainly involved in the control
of oxidative stress and is downregulated in the seminal
plasma of asthenozoospermic men [21]. DJ-1 is activated
in stress conditions, but with higher levels of stress (as
seen in OA), there is depletion of antioxidant levels and
low expression of DJ-1 protein. Furthermore, the major
biological function that comes into focus through IPA in
the NA group is free-radical scavenging activity. This fur-
ther supports the fact that DJ-1 was activated in the NA
group. Significant proteins were distributed in the lyso-
somal and vacuolar regions in higher amounts in the OA
group (Figure 3), suggesting that proteins with phagocytic
activity may be activated in stress conditions. Previous
studies have reported reduced levels of DJ-1 in sperm in
response to toxic exposure of male rats to ornidazole and
epichlorhydrin [70].
Utleg et al. categorized prostatic acid phosphatase
(PAP) precursor as an enzymatic protein, and the pres-
ence of this protein in our study suggests that it plays a
similar role [39]. The distribution pattern of immune
system response in all the groups is shown in Figure 4.
It is likely that B2MG is the major protein in immuneresponse and that low levels of this protein are seen in
stress conditions. Low distribution of B2MG in DEP
compared to normal and low abundant proteins further
suggests that in addition to B2MG, there are other pro-
teins that also play a key role in immune system processes.
We further validated this observation from the pathway
analysis, which showed that that the common protein
prosaposin isoform, a preprotein, is involved in lipid anti-
gen presentation by CD1.
We observed overlapping of differentially expressed
proteins with the low abundant proteins in our study.
These included transferrin, secretory leukocyte peptidase
inhibitor precursor, ubiquitin and ribosomal protein
S27a precursor, protein tyrosine phosphatase, receptor
type, sigma isoform 1 precursor and acidic epidiymal
glycoprotein- like 1 isoform 1 precursor. Of these pro-
teins, protein tyrosine phosphatase, receptor type, sigma
isoform 1 precursor, acidic epididymal glycoprotein-like
isoform 1 precursor were amongst the low abundant
proteins. Protein tyrosine phosphatase, receptor type,
sigma isoform 1 precursor were upregulated while acidic
epididymal glycoprotein-like isoform 1 precursor was
down regulated in the NA group. The acidic epididymal
glycoprotein like I isoform I precursor is a member of
the cysteine - rich secretory protein (CRISP) family and
is encoded by the gene CRISP-I. It is expressed in the
epididymis and is secreted into the epididymal lumen. It
binds to the post acrosomal region of the head, where it
may play a role in sperm-egg fusion. The reported low
abundance of acidic epididymal glycoprotein like I iso-
form I precursor protein is concordant with the findings
of Batruch et al. who also reported its low abundance in
the seminal plasma of post vasectomy patients compared
to controls [8].
Transferrin is one of the serum proteins that has been
characterized in the seminal plasma, but its role in male
infertility is unclear [20]. Our study showed this protein
was present in low levels in the NN group but was up
regulated in NA and OA groups. Prostaglandin H2 D
isomerase, cathepsin B preprotein, orosomucoid 2 and
the CD177 molecule were the low abundant proteins that
were not differentially expressed in any of the groups. In
our study, CD177 was absent in the NN group but present
in all the other groups although they were not
differentially expressed. Our findings are consistent with
previous publications that reported low concentrations of
CD177 in fertile men (control samples) compared to
postvasectomy men [8] but are contrary to the findings of
Wang et al. who reported upregulation of CD177 in
asthenozoospermic patients [21]. Cathepsin B preprotein
was present in the NN and NA groups, showing its speci-
ficity to the normal sperm count while prostaglandin H2
D isomerase was absent in the ON group. Cathepsin B
preprotein found in the lysosomal region is a thiol
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ation. It has also been implicated in tumor invasion and
metastasis. The prostaglandin (H2) D-isomerase is
expressed in the testis, epididymis and prostate and is se-
creted into the seminal fluid. It binds small non-substrate
lipophilic molecules and may act as a scavenger for harm-
ful hydrophobic molecules. The prostaglandin (H2) D-
isomerase and cathepsin B protein are potentially involved
in biological processes such as vesicle-mediated transport
and defense response. The low abundant proteins showed
a marked distribution in the extracellular region and may
play a regulatory role. The major pathways in which the
low abundant proteins were involved were prostanoid bio-
synthesis and eicosanoid signaling and acute phase re-
sponse signaling, but the distribution of signal
transduction proteins was decreased in low abundant
proteins.Conclusions
In the present study, we have identified proteins that are
common, unique, and differentially expressed in 4 study
groups. Twenty proteins were differentially expressed in
the seminal plasma of men with poor sperm quality. We
have highlighted the distribution pattern of these pro-
teins in cell organelles and described their biological
processes. We have also illustrated the high involvement
of proteins in cellular development signal transduction.
The overexpression or underexpression of these proteins
in the 4 groups illustrates their role in male infertility.
Our findings from the bioinformatic analysis shows that
stress proteins such as DJ-1 are differentially regulated
and expressed in the different study groups, suggesting
that some of these proteins may serve as a potential bio-
markers in identifying the mechanistic role in men with
poor sperm quality.
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